Seeking Alpha

pwt750

pwt750
Send Message
View as an RSS Feed
View pwt750's Comments BY TICKER:
Latest comments  |  Highest rated
  • The Captain Of Amarin's Listless Ship Makes Ready For The Storm [View article]
    far from a complete review but allI have time for now ;

    I must fault the practical logic of "extensive preparations seem to contradict your declarations of faith." while I broaden your statement "battle is exactly what Amarin [should be and ] is preparing for."
    Come on, he talks confidence and it's hollow bravado, he speaks caution and it's a dire tell. And the Devil. and the Hard Place.

    "I avoid binary events. There seems to be little to gain by holding through them and much to lose." Often, I guess. We now have a class of speculators who settle for less (and many small losses) in order to avoid conviction positions. I well recall the recent ACAD tumult, with adam crying "selective data mining", where folks were joyful of flat~10~30% by dumping before data. Despite that the data to be revealed was actually already available, gleaned from previous work. Note ACAD is over $25 today. ( my modest 2, 6 and 14 positions are still in hand so my opinion is admittedly corrupted).

    Now "Some things are better left unsaid." Between friends, wives and lovers ( may they never meet) , perhaps. But this is war and the re-imbursement battle for a large chunk of L's market is about to sea change.


    The last note I can offer fr now is the effect of a positive Anchor data PR.

    date ….......open / high / low / close...........vol
    4.15.11...…8.52 / 8.82 / 8.46 / 8.77…….....2,298,723
    4.18.11.....15.74 / 17.44 / 14.21 / 17.10…..53,541,133

    gotta run, good luck
    Sep 20 12:07 PM | 9 Likes Like |Link to Comment
  • Dare I Say Amarin Looks Bullish On Good News? [View article]
    dude your articles are so lightweight yet annoyingly shallow, the financial equivalent of Entertainment Weakly, that its totally unfair to call them 'bashing'. More like a bird's pecking. I must admit I was tricked to arrive here but nevermore
    May 30 01:02 PM | 7 Likes Like |Link to Comment
  • Hercules Offshore - Becoming A Market Leader In HPHT Drilling [View article]
    here is some more interesting information ;

    there is a well regarded, knowledgeable, and long time poster on HERO yahoo board who is detailing & documenting his evidence and opinions on the rampant apparent naked shorting that has tied HERO near these lows. His current conclusion is that GS is probably behind this, and that without phantom shares and naked shorts this stock ought not even have shares available to trade in the volumes recorded …

    This poster also claims he has had a long time ID hacked, he changed IDs and continued posting , and his new ID posts are disappearing within moments.
    Other posters there are copying & pasting the OPs posts, and these TOO are disappearing in minutes if not seconds. No profanity, no TOS violations, just pure simple substantial opinions on the questionable trading HERO 'enjoys'.

    Sorry for being vague, I leave it to the original poster to reveal more about the situation ( I know he reads SA) but between yahoo and IH, interested parties should be able to understand the situation, and perhaps increase the chorus of complaints to the SEC for stock manipulation using public message boards.

    The corruption this implies is staggering … I recommend all interested honest readers ( this kind of excludes the short + distort crowd involved in this terminal game) REPORT THE MANIPULATION TO THE SEC
    May 28 01:31 PM | 5 Likes Like |Link to Comment
  • Thumbs Down To Amarin's ANCHOR Would Sink Its Ship [View article]
    "Amarin Announces Completion of Offering of American Depositary Shares... resulting in net proceeds to Amarin of approximately $121.1 million"

    you call it 12.1 mill and run your math on it ? Wing it , much?

    Yeah I want to get my advice from you.
    Oct 11 08:03 PM | 5 Likes Like |Link to Comment
  • AF Backtracking, AMRN Will Be Approved On Time [View instapost]
    I find it irrational that the FDA would make it a condition that AMRN conduct a hugely expensive outcomes trial, and then cut off the company from the means of support to finish that trial.

    Given the excellent safety signals of EPA, and with the only long term trial of an EPA-only drug returning positive results, along with the fact that drugs failing an outcomes are still on market and widely used, I hope that FDA is indeed rational.

    It will be interesting to see if anyone on the committee has an agenda, or worse conflicted interests, to taint the logic. When you say "the panel agree[s] that waiting for CVOT data before expanding Vascepa's label is the correct action to take" it shows the difference between a 'journalist' and a reporter. A bias, and a seemingly bitter one at that, having seen the derision you save for AMRN and it's stockholders. I hope no one you care about would be required to wait 2 more years, they may not have, to see if taking a clean profile drug is any good for them. Not to mention , although not robust, the additional data from all those regular patients would help settle the questions.

    Let physicians and patients decide if they have time to fritter around a few years.
    Sep 25 10:18 PM | 5 Likes Like |Link to Comment
  • Vascepa Data Should Make Amarin Longs Worried [View article]
    I was tricked into submitting eyeballs on to this wishy washy report ("either going to be extremely successful or an extreme failure" ... LOL) , and although I promise to be more protective next time with my remaining brain cells, while I'm here here's a few more charts for consideration;

    The Lovaza::Vascepa ratio, care of st's pipette_cry_repeat;
    http://bit.ly/10Jb1Xy
    Interesting wouldn't you say ? Any predictions where this curve headed? GSK, are you with me here ?

    Here is Pronova's own proud declaration of early Lovaza (monthly) growth. Might notice some oscillations there ... on its way upNup. I can only imagine the Chortles of Doom with each tick down that had to be choked back on a data point later. http://bit.ly/12PFLF8

    PS, Vascepa still has the second trend lurking in its' shadows.
    Will need to re-scale it for ANCHOR-2013
    May 20 01:36 PM | 5 Likes Like |Link to Comment
  • Price Target Update For Amarin (AMRN) [View instapost]
    bullscam; nice first post.

    Fair is fair ; whats is your sentiment, your share count (or short , or put or call strike & date ) count and & price. And what is your REAL name? May I call to verify ?
    May 8 10:14 PM | 5 Likes Like |Link to Comment
  • The Future Of Omega-3 Based Lipid Management: All Eyes On Amarin [View article]
    William Haynes -

    Possibly you will be flamed by some, but not by more serious minds looking at this topic. Surely you see the difference, so pls forgive us as a whole even though we are not.

    There is a Haynes, William G., MD associated with University of Iowa Hospitals and Clinics. Are you he ?

    I realize it is not your quote but since you brought it up, I found Dr Topol's strong language very interesting; "I implore them to stop taking it". As you did mention "for 17 years and using fish oil to treat triglycerides" do you see any reason to "beg someone earnestly or desperately to..." stop taking fish oils ?

    Also you refer to alternately to fish oils and EPA. ( this may well be the source of the combustion you foretell :) Do you see no, or any, difference between fish oils and the fish oil derived product ethyl ester EPA, in the matter at hand ?

    Have you done any study into the anti-inflammatory aspects (re effecting the arachidonic acid levels , and relation to the omega 6 levels in the western diet) evident for EPA which some claim underlays the expectation for EPA's utility in CVD treatment, while trig effects may be almost peripheral to the root problem.

    thanks in advance.
    Jun 2 12:15 PM | 4 Likes Like |Link to Comment
  • Hercules Offshore - Becoming A Market Leader In HPHT Drilling [View article]
    There is something NOT right going on with this ticker and hopefully it will blow up in the face of the marker manipulator that is conducting the attack.

    While on the yahoo board there is the usual gaggle of shorts recycling the same loud claims in attempt to bury any fresh comments, but there were about 20~30 posts of an informed and detailed nature analyzing the short / naked / flash trade manipulating this name. ALL those posts disappeared. Copies of those posts disappeared. No objectionable content, just vanished.

    Look to your SA PMs with a good lead into this information, I hope you two move forward with the expose. (ps having a little trouble with SA PM at this moment, will be in touch…)
    May 28 01:57 PM | 3 Likes Like |Link to Comment
  • Thumbs Down To Amarin's ANCHOR Would Sink Its Ship [View article]
    DECIMAL POINT FIXED !?!??! rawnoc, You USED the $12M in your calcs ! I see you also fixed that preposterous math fubar too that came along with that glaring error, but you don't suppose granting the company an extra HUNDRED TEN MILLION might sway analysis just a wee tad?

    shees.

    Other than 2~3 years of bank roll you MISSED TOTALLY, I must say "what an article ..."
    Oct 11 09:57 PM | 3 Likes Like |Link to Comment
  • Amarin Corporation CEO Discusses Q1 2013 Results - Earnings Call Transcript [View article]
    thanks for the transcript service , tho this one looks like it needs some punching up for accuracy .

    Of course the passage "I think it depends on the day for us, it’s about jealous. That’s the best comparator for our study, for our drug. And jealous is the study that in Japan saw a 19% reduction in mortality with our..."

    refers to JELIS study, not jealous :) just ask any time !
    May 10 01:51 AM | 3 Likes Like |Link to Comment
  • Synovus sets 1:7 reverse stock split [View news story]
    Synovus ticker symbol is NOT "SYN".
    Apr 25 08:39 AM | 2 Likes Like |Link to Comment
  • Vascepa Scripts Keep Screaming For Amarin [View article]
    See US National Library of Medicine, National Institutes of Health

    http://1.usa.gov/16v2J4k

    Conclusion
    Dyerberg and colleagues examined the relationship between EPA and CVD, and the JELIS study recently demonstrated that EPA administration reduces the risk of CVD. An important difference between EPA and DHA is the metabolism of EPA to bioactive PGI3. It is assumed that, similar to PGI2, PGI3 inhibits platelet aggregation, vascular contrac- tion, myocardial ischemic injury and arteriosclerosis and induces neoangiogenesis. Therefore, it is specu- lated that the CVD risk reduction induced by EPA is also associated with the effects of PGI3 in addition to the numerous effects of EPA itself (such as TG reduc- tion, inflammation inhibition and improvements in plasma membrane fluidity). This hypothesis is con- firmed by the following findings: an increased CVD risk was found to be associated with a reduction in the EPA/AA ratio, and the EPA/AA ratio was found to be positively correlated with the (PGI2+PGI3)/TXA2 ratio.
    Sep 24 12:43 AM | 2 Likes Like |Link to Comment
  • MORE POTENTIAL NEWS FOR AMRN [View instapost]
    Today, Pfizer is announcing plans to move forward to internally separate its commercial operations into three business segments, two of which will include Innovative business lines and a third which will include the Value business line...

    One of the Innovative business segments ... will generally include products across multiple therapeutic areas that are expected to have market exclusivity beyond 2015. The therapeutic areas include Inflammation and Immunology, CV/Metabolic, Neuroscience and Pain, Rare Diseases and Women's/Men's Health ... the other Innovative business segment will include Vaccines, Oncology and Consumer Healthcare...

    The Value business segment ... will include products that generate strong, consistent cash flow, and will be positioned to provide patients access to effective, lower-cost, high-value treatments. In addition to products that have lost market exclusivity, it will generally include mature, patent-protected products that are expected to lose exclusivity through 2015 in most major markets, biosimilars and current and future established products collaborations...
    Jul 29 05:02 PM | 2 Likes Like |Link to Comment
  • Hercules Offshore: Fleet Analysis As Of July 23 And Recent Second Quarter Results [View article]
    Chancer- HERO traded $6 to $8 almost the entire 2013 year. Watch a little closer next time
    http://bit.ly/1Ay70q9
    Jul 30 07:54 AM | 1 Like Like |Link to Comment
COMMENTS STATS
67 Comments
60 Likes